Autologous haematopoietic stem-cell transplantation in multiple sclerosis: Benefits and risks

E. Capello, L. Vuolo, F. Gualandi, M. T. Van Lint, L. Roccatagliata, L. Bonzano, M. Pardini, A. Uccelli, Gianluigi Mancardi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Autologous haematopoietic stem-cell transplantation has been evaluated over the last years as a possible new therapeutic strategy in severe forms of multiple sclerosis unresponsive to the approved therapies. Up to now, more than 400 patients have been treated and numerous are the phase I and phase II studies which addressed the feasibility of this treatment, the efficacy, side effects and transplant-related mortality. The clinical response is strongly related to the intensity of the conditioning regimen utilized as well as to the phase of the disease course in which the therapy is carried out. Rapidly evolving multiple sclerosis with a relapsing-remitting clinical course and MRI signs of activity are the cases that can take more advantage. The risk of mortality, which dropped in the last years to 2-3%, is still the main problem of this powerful therapy.

Original languageEnglish
JournalNeurological Sciences
Volume30
Issue numberSUPPL. 2
DOIs
Publication statusPublished - 2009

Fingerprint

Hematopoietic Stem Cell Transplantation
Multiple Sclerosis
Mortality
Therapeutics
Transplants

Keywords

  • Autologous stem-cell transplantation
  • Intense immunosuppression in multiple sclerosis
  • Malignant forms of multiple sclerosis
  • Multiple sclerosis

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology

Cite this

Autologous haematopoietic stem-cell transplantation in multiple sclerosis : Benefits and risks. / Capello, E.; Vuolo, L.; Gualandi, F.; Van Lint, M. T.; Roccatagliata, L.; Bonzano, L.; Pardini, M.; Uccelli, A.; Mancardi, Gianluigi.

In: Neurological Sciences, Vol. 30, No. SUPPL. 2, 2009.

Research output: Contribution to journalArticle

Capello, E, Vuolo, L, Gualandi, F, Van Lint, MT, Roccatagliata, L, Bonzano, L, Pardini, M, Uccelli, A & Mancardi, G 2009, 'Autologous haematopoietic stem-cell transplantation in multiple sclerosis: Benefits and risks', Neurological Sciences, vol. 30, no. SUPPL. 2. https://doi.org/10.1007/s10072-009-0144-5
Capello, E. ; Vuolo, L. ; Gualandi, F. ; Van Lint, M. T. ; Roccatagliata, L. ; Bonzano, L. ; Pardini, M. ; Uccelli, A. ; Mancardi, Gianluigi. / Autologous haematopoietic stem-cell transplantation in multiple sclerosis : Benefits and risks. In: Neurological Sciences. 2009 ; Vol. 30, No. SUPPL. 2.
@article{f16ebd0387534c1a855038357b2fdae5,
title = "Autologous haematopoietic stem-cell transplantation in multiple sclerosis: Benefits and risks",
abstract = "Autologous haematopoietic stem-cell transplantation has been evaluated over the last years as a possible new therapeutic strategy in severe forms of multiple sclerosis unresponsive to the approved therapies. Up to now, more than 400 patients have been treated and numerous are the phase I and phase II studies which addressed the feasibility of this treatment, the efficacy, side effects and transplant-related mortality. The clinical response is strongly related to the intensity of the conditioning regimen utilized as well as to the phase of the disease course in which the therapy is carried out. Rapidly evolving multiple sclerosis with a relapsing-remitting clinical course and MRI signs of activity are the cases that can take more advantage. The risk of mortality, which dropped in the last years to 2-3{\%}, is still the main problem of this powerful therapy.",
keywords = "Autologous stem-cell transplantation, Intense immunosuppression in multiple sclerosis, Malignant forms of multiple sclerosis, Multiple sclerosis",
author = "E. Capello and L. Vuolo and F. Gualandi and {Van Lint}, {M. T.} and L. Roccatagliata and L. Bonzano and M. Pardini and A. Uccelli and Gianluigi Mancardi",
year = "2009",
doi = "10.1007/s10072-009-0144-5",
language = "English",
volume = "30",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Autologous haematopoietic stem-cell transplantation in multiple sclerosis

T2 - Benefits and risks

AU - Capello, E.

AU - Vuolo, L.

AU - Gualandi, F.

AU - Van Lint, M. T.

AU - Roccatagliata, L.

AU - Bonzano, L.

AU - Pardini, M.

AU - Uccelli, A.

AU - Mancardi, Gianluigi

PY - 2009

Y1 - 2009

N2 - Autologous haematopoietic stem-cell transplantation has been evaluated over the last years as a possible new therapeutic strategy in severe forms of multiple sclerosis unresponsive to the approved therapies. Up to now, more than 400 patients have been treated and numerous are the phase I and phase II studies which addressed the feasibility of this treatment, the efficacy, side effects and transplant-related mortality. The clinical response is strongly related to the intensity of the conditioning regimen utilized as well as to the phase of the disease course in which the therapy is carried out. Rapidly evolving multiple sclerosis with a relapsing-remitting clinical course and MRI signs of activity are the cases that can take more advantage. The risk of mortality, which dropped in the last years to 2-3%, is still the main problem of this powerful therapy.

AB - Autologous haematopoietic stem-cell transplantation has been evaluated over the last years as a possible new therapeutic strategy in severe forms of multiple sclerosis unresponsive to the approved therapies. Up to now, more than 400 patients have been treated and numerous are the phase I and phase II studies which addressed the feasibility of this treatment, the efficacy, side effects and transplant-related mortality. The clinical response is strongly related to the intensity of the conditioning regimen utilized as well as to the phase of the disease course in which the therapy is carried out. Rapidly evolving multiple sclerosis with a relapsing-remitting clinical course and MRI signs of activity are the cases that can take more advantage. The risk of mortality, which dropped in the last years to 2-3%, is still the main problem of this powerful therapy.

KW - Autologous stem-cell transplantation

KW - Intense immunosuppression in multiple sclerosis

KW - Malignant forms of multiple sclerosis

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=74049122036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74049122036&partnerID=8YFLogxK

U2 - 10.1007/s10072-009-0144-5

DO - 10.1007/s10072-009-0144-5

M3 - Article

C2 - 19882370

AN - SCOPUS:74049122036

VL - 30

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - SUPPL. 2

ER -